

Bill Summary
1st Session of the 60th Legislature

Bill No.:	SB 1064
Version:	INT
Request No.	760
Author:	Sen. Rosino
Date:	01/27/2025

Bill Analysis

SB 1064 provides that if a prescription drug that is subject to step therapy protocol is approved by the FDA for the treatment of a rare disease and no clinical practice guidelines are available for the rare disease, no restrictions imposed by the protocol shall be any more restrictive than in accordance with the conditions of use included in the FDA required labeling for the prescription drug.

Prepared by: Kalen Taylor